Content by Anglia Ruskin University
|2 min read
First T-Cell Therapy Improves Survival in ARDS Patients
Phase 1/2 trial data suggest that iNKT-cell therapy reduced systemic inflammation and pneumonia risk in patients on VV-ECMO|2 min read
New COVID-19 Test Produces Reliable Results in 20 Minutes
The Cov2-ID qPCR test targets three viral genes instead of two, increasing reliabilityPage 1 of 1





